JPM Interview: Lilly CEO Lechleiter On The Cost Of Innovation
This article was originally published in Scrip
Eli Lilly & Co. is back on the path to growth with new products being added to its revenue mix, and CEO John Lechleiter wants to make sure that the company's and the biopharma industry's investments in research for new drugs are protected.
You may also be interested in...
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.